Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-24 01:34 | 2026-01-21 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Officer | SELL | $72.45 | 4,895 | $354,643 | 31,599 |
| 2026-01-24 01:34 | 2026-01-21 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Director, Officer | SELL | $72.45 | 14,387 | $1,042,338 | 269,007 |
| 2026-01-24 01:33 | 2026-01-21 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Officer | SELL | $72.45 | 6,534 | $473,388 | 85,093 |
| 2026-01-24 01:33 | 2026-01-21 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | Officer | SELL | $72.45 | 2,929 | $212,206 | 113,938 |
| 2026-01-24 01:42 | 2026-01-22 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $56.36 | 3,324 | $187,357 | 449,844 |
| 2026-01-24 00:05 | 2026-01-21 | PVLA | PALVELLA THERAPEUTICS, INC. | Goin Kathleen | Officer | OPT+S | $97.63 | 4,302 | $419,983 | 0 |
| 2026-01-24 03:00 | 2026-01-22 | AXSM | Axsome Therapeutics, Inc. | Pizzie Nick | Officer | OPT+S | $187.92 | 12,000 | $2,255,040 | 42,588 |
| 2026-01-24 03:00 | 2026-01-21 | AXSM | Axsome Therapeutics, Inc. | Maizel Ari | Officer | OPT+S | $184.44 | 7,500 | $1,383,300 | 0 |
| 2026-01-24 00:13 | 2026-01-22 | APLS | Apellis Pharmaceuticals Inc. | Baumal Caroline | Officer | SELL | $21.77 | 2,797 | $60,878 | 86,527 |
| 2026-01-24 00:12 | 2026-01-22 | APLS | Apellis Pharmaceuticals Inc. | Chopas James George | Officer | SELL | $21.77 | 2,064 | $44,924 | 49,805 |
| 2026-01-24 00:11 | 2026-01-22 | APLS | Apellis Pharmaceuticals Inc. | DeLong Mark Jeffrey | Officer | SELL | $21.77 | 3,371 | $73,371 | 78,353 |
| 2026-01-24 00:10 | 2026-01-22 | APLS | Apellis Pharmaceuticals Inc. | Deschatelets Pascal | Officer | SELL | $21.77 | 5,928 | $129,025 | 1,151,382 |
| 2026-01-24 00:09 | 2026-01-22 | APLS | Apellis Pharmaceuticals Inc. | Francois Cedric | Director, Officer | SELL | $21.77 | 27,192 | $591,845 | 286,045 |
| 2026-01-24 00:08 | 2026-01-22 | APLS | Apellis Pharmaceuticals Inc. | Nicholson Nur | Officer | SELL | $21.77 | 7,725 | $168,138 | 71,118 |
| 2026-01-24 00:07 | 2026-01-22 | APLS | Apellis Pharmaceuticals Inc. | Sullivan Timothy Eugene | Officer | SELL | $21.77 | 10,287 | $223,901 | 93,901 |
| 2026-01-24 00:05 | 2026-01-22 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $21.77 | 7,832 | $170,467 | 88,531 |
| 2026-01-24 01:33 | 2026-01-21 | RNA | Avidity Biosciences, Inc. | MacLean Michael F | Officer | SELL | $72.45 | 4,542 | $329,068 | 59,290 |
| 2026-01-23 20:35 | 2026-01-22 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $2.95 | 2,500 | $7,375 | 0 |
| 2026-01-24 01:30 | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC | Officer | OPT+S | $93.33 | 1,421 | $132,615 | 42,127 |
| 2026-01-24 01:33 | 2026-01-21 | RNA | Avidity Biosciences, Inc. | LEVIN ARTHUR A | Director | SELL | $72.45 | 1,758 | $127,367 | 16,562 |
| 2026-01-23 04:33 | 2026-01-22 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | Officer | SELL | $5.33 | 13,578 | $72,383 | 451,134 |
| 2026-01-23 04:33 | 2026-01-22 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | Director, Officer | SELL | $5.33 | 69,832 | $372,267 | 1,460,408 |
| 2026-01-23 03:31 | 2026-01-20 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $35.67 | 3,867 | $137,936 | 21,354 |
| 2026-01-23 01:24 | 2026-01-20 | NAMS | NewAmsterdam Pharma Co N.V. | Somaiya Mayur Ian | Officer | OPT+S | $32.61 | 100,000 | $3,260,620 | 58,382 |
| 2026-01-23 05:46 | 2026-01-20 | PLRX | PLIANT THERAPEUTICS, INC. | Cummings Keith Lamont | Officer | SELL | $1.28 | 24,002 | $30,723 | 297,214 |
| 2026-01-23 05:38 | 2026-01-20 | PLRX | PLIANT THERAPEUTICS, INC. | Cheung Lily | Officer | SELL | $1.28 | 7,534 | $9,644 | 44,847 |
| 2026-01-23 05:38 | 2026-01-20 | PLRX | PLIANT THERAPEUTICS, INC. | Coulie Bernard | Director, Officer | SELL | $1.28 | 89,375 | $114,400 | 505,601 |
| 2026-01-23 05:38 | 2026-01-20 | PLRX | PLIANT THERAPEUTICS, INC. | Kuo Minnie | Officer | SELL | $1.28 | 6,917 | $8,854 | 37,806 |
| 2026-01-23 03:00 | 2026-01-20 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | Director, Officer | SELL | $26.12 | 10,916 | $285,071 | 25,812 |
| 2026-01-23 04:34 | 2026-01-22 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | Officer | SELL | $5.33 | 18,666 | $99,507 | 568,560 |
| 2026-01-23 01:34 | 2026-01-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $26.75 | 20,000 | $535,098 | 745,188 |
| 2026-01-23 04:09 | 2026-01-22 | COGT | Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Director | SELL | $36.40 | 3,500,000 | $127,400,000 | 5,503,418 |
| 2026-01-23 01:33 | 2026-01-20 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Director | SELL | $26.75 | 1,230 | $32,902 | 23,877 |
| 2026-01-22 15:00 | 2026-01-21 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $1.00 | 10,000 | $9,975 | 798,460 |
| 2026-01-23 00:09 | 2026-01-21 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Officer | SELL | $5.96 | 265 | $1,579 | 22,580 |
| 2026-01-23 05:30 | 2026-01-21 | CRMD | CorMedix Inc. | Dillione Janet | Director | SELL | $6.88 | 10,000 | $68,800 | 38,473 |
| 2026-01-23 03:26 | 2026-01-20 | FOLD | AMICUS THERAPEUTICS, INC. | Campbell Bradley L | Director, Officer | OPT+S | $14.31 | 75,000 | $1,073,183 | 1,021,180 |
| 2026-01-22 21:04 | 2025-12-12 | OGEN | ORAGENICS INC | Telling Fred | Director | SELL | $0.94 | 210 | $198 | 948 |
| 2026-01-23 00:28 | 2026-01-20 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $158.93 | 10,699 | $1,700,411 | 306,891 |
| 2026-01-23 03:41 | 2026-01-21 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $41.82 | 27,845 | $1,164,548 | 16,680 |
| 2026-01-22 02:13 | 2026-01-16 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $4.97 | 32,474 | $161,519 | 617,824 |
| 2026-01-22 02:55 | 2026-01-20 | IRON | Disc Medicine, Inc. | Khara Rahul | Officer | OPT+S | $69.74 | 1,000 | $69,740 | 37,793 |
| 2026-01-21 17:09 | 2026-01-16 | IMRX | Immuneering Corp | Brakewood Harold Eugene | Officer | BUY | $4.76 | 5,250 | $24,990 | 11,050 |
| 2026-01-22 05:00 | 2026-01-20 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Director | SELL | $26.88 | 10,000 | $268,800 | 727,770 |
| 2026-01-21 20:46 | 2026-01-21 | XCUR | EXICURE, INC. | Exicure HiTron Inc. | 10% owner | SELL | $4.50 | 258,367 | $1,162,652 | 1,598,947 |
| 2026-01-22 00:05 | 2026-01-20 | MIRM | Mirum Pharmaceuticals, Inc. | Quan Joanne | Officer | OPT+S | $90.27 | 6,911 | $623,853 | 11,305 |
| 2026-01-22 00:19 | 2026-01-20 | APLS | Apellis Pharmaceuticals Inc. | Baumal Caroline | Officer | SELL | $19.79 | 1,882 | $37,250 | 89,324 |
| 2026-01-22 00:18 | 2026-01-20 | APLS | Apellis Pharmaceuticals Inc. | Chopas James George | Officer | SELL | $19.79 | 726 | $14,370 | 51,869 |
| 2026-01-22 00:17 | 2026-01-20 | APLS | Apellis Pharmaceuticals Inc. | DeLong Mark Jeffrey | Officer | SELL | $19.79 | 1,334 | $26,404 | 81,724 |
| 2026-01-22 00:16 | 2026-01-20 | APLS | Apellis Pharmaceuticals Inc. | Deschatelets Pascal | Officer | SELL | $19.79 | 909 | $17,992 | 1,157,310 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.